DK0832069T3 - Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) - Google Patents

Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)

Info

Publication number
DK0832069T3
DK0832069T3 DK95918722T DK95918722T DK0832069T3 DK 0832069 T3 DK0832069 T3 DK 0832069T3 DK 95918722 T DK95918722 T DK 95918722T DK 95918722 T DK95918722 T DK 95918722T DK 0832069 T3 DK0832069 T3 DK 0832069T3
Authority
DK
Denmark
Prior art keywords
apolipoprotein
apo
biphenyl
secretion
inhibitors
Prior art date
Application number
DK95918722T
Other languages
Danish (da)
English (en)
Inventor
George J Quallich
George Chang
Peter H Dorff
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/IB1995/000448 external-priority patent/WO1996040640A1/en
Application granted granted Critical
Publication of DK0832069T3 publication Critical patent/DK0832069T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK95918722T 1995-06-07 1995-06-07 Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) DK0832069T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000448 WO1996040640A1 (en) 1995-06-07 1995-06-07 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Publications (1)

Publication Number Publication Date
DK0832069T3 true DK0832069T3 (da) 2003-04-22

Family

ID=11004342

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95918722T DK0832069T3 (da) 1995-06-07 1995-06-07 Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)

Country Status (20)

Country Link
US (1) US5919795A (de)
KR (1) KR100225713B1 (de)
AR (1) AR003424A1 (de)
AT (1) ATE233734T1 (de)
AU (1) AU703493B2 (de)
BG (1) BG62442B1 (de)
CO (1) CO4440626A1 (de)
DE (1) DE69529849T2 (de)
DK (1) DK0832069T3 (de)
DZ (1) DZ2045A1 (de)
IL (3) IL135377A (de)
MA (1) MA23895A1 (de)
MX (1) MX9709914A (de)
OA (1) OA10363A (de)
RO (1) RO116897B1 (de)
RU (1) RU2141478C1 (de)
TN (1) TNSN96085A1 (de)
TR (1) TR199600481A2 (de)
TW (1) TW476756B (de)
YU (1) YU35296A (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711279B2 (en) * 1996-04-30 1999-10-07 Pfizer Inc. Processes and intermediates for preparing 4'-trifluoromethylbiphenyl-2-carboxylic acid (2-(2H-(1,2,4)triazol-3-ylmethyl)-1,2, 3,4-tetrahydro-isoquinolin-6-yl)-amide
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
AU2001237309A1 (en) * 2000-01-18 2001-07-31 Novartis Ag Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US6953671B2 (en) * 2001-02-23 2005-10-11 The Trustees Of Columbia University In The City Of New York Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action
BR0210616A (pt) 2001-06-28 2004-09-28 Pfizer Prod Inc Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
US7241774B2 (en) * 2002-03-13 2007-07-10 University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
EP1687299A1 (de) * 2003-11-20 2006-08-09 Eli Lilly And Company Heterocyclische verbindungen als modulatoren von durch den peroxisomproliferator aktivierten rezeptoren, die sich zur behandlung und/oder prävention von durch einen ppar modulierten erkrankungen eignen
OA13365A (en) 2004-02-04 2007-04-13 Pfizer Prod Inc Substituted quinoline compounds.
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
EP1877369B1 (de) * 2005-04-19 2013-07-10 Surface Logix, Inc. Inhibitoren des mikrosomalen triglyceridtransfer-proteins und der apo-b-sekretion
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
EA201100812A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
EP2076597A2 (de) * 2006-10-09 2009-07-08 Santaris Pharma A/S Rna-antagonistenverbindungen zur modulation von pcsk9
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CA2681406A1 (en) * 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
JP2010537958A (ja) * 2007-08-30 2010-12-09 サンタリス ファーマ アー／エス Ｆａｂｐ４／ａｐ２を調節するためのｒｎａアンタゴニスト化合物
AU2008306327B2 (en) * 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
EP2268811A1 (de) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
PE20110574A1 (es) * 2008-10-29 2011-08-11 Hoffmann La Roche Derivados de fenilamida y de piridilamida como agonistas de gpbar1
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US20100280067A1 (en) * 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
WO2010127208A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
CA2817093A1 (en) * 2010-11-15 2012-05-24 Abbvie Inc. Nampt inhibitors
KR101931089B1 (ko) 2013-06-27 2019-03-14 로슈 이노베이션 센터 코펜하겐 에이/에스 Pcsk９ 를 표적화하는 안티센스 올리고머 및 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
CA1248536A (en) * 1982-09-10 1989-01-10 Wellcome Foundation Limited (The) Benzoil acid derivatives
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
NZ335162A (en) * 1996-11-27 2000-01-28 Pfizer Apo b-secretion/mtp inhibitory amides

Also Published As

Publication number Publication date
IL135377A0 (en) 2001-05-20
TW476756B (en) 2002-02-21
DE69529849D1 (de) 2003-04-10
KR100225713B1 (ko) 1999-10-15
ATE233734T1 (de) 2003-03-15
DZ2045A1 (fr) 2002-07-21
IL135376A (en) 2001-05-20
DE69529849T2 (de) 2003-09-04
IL135375A (en) 2001-07-24
TNSN96085A1 (fr) 2005-03-15
CO4440626A1 (es) 1997-05-07
MA23895A1 (fr) 1996-12-31
YU35296A (sh) 1999-06-15
US5919795A (en) 1999-07-06
MX9709914A (es) 1998-03-31
BG62442B1 (bg) 1999-11-30
IL135376A0 (en) 2001-05-20
KR970003589A (ko) 1997-01-28
IL135377A (en) 2001-05-20
AU5478496A (en) 1996-12-19
RU2141478C1 (ru) 1999-11-20
IL135375A0 (en) 2001-05-20
TR199600481A2 (tr) 1996-12-21
OA10363A (en) 2001-11-15
BG100637A (bg) 1997-03-31
AU703493B2 (en) 1999-03-25
AR003424A1 (es) 1998-08-05
RO116897B1 (ro) 2001-07-30

Similar Documents

Publication Publication Date Title
DK0832069T3 (da) Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
FI974440A0 (fi) Bifenyyli-2-karboksyylihappo-tetrahydro-isokinolin-6-yyli-amidijohdannaisia, niiden valmistus ja niiden käyttö mikrosomaalistatriglyseridiä siirtävän proteiinin ja/tai apolipoproteiini B:n (Apo B) erittymiseen inhibiittoreina
NO996491L (no) 4-brom- eller 4-iod-fenylaminobenzhydroksamsyre-derivater og deres anvendelse som MEK-inhibitorer
NO941679D0 (no) Gallesyrederivater, fremgangsmåte for fremstilling og deres anvendelse
DK641589A (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
DK1058725T3 (da) Anvendelse af bakterier, som indeholder arginindeiminase, til induktion af apoptose og/eller reduktion af en inflammatorisk reaktion og farmaceutiske eller diætetiske præparater, der indholder sådanne bakterier
NO20012688L (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
DK0526543T3 (da) Derivater og analoger af 2-deoxy-2,3-didehydro-N-acetylneuraminsyre og deres anvendelse som antivirale midler
DK118791A (da) 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner, deres fremstilling og anvendelse som eller til fremstilling af laegemidler
DK326989A (da) Alminoalkylaminocarbonylaminodiolaminosyrederivater og deres anvendelse som renininhibitorer
DK1006110T3 (da) Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler
DK0910573T3 (da) Nye aminosyrederivater og deres anvendelse som thrombininhibitorer
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO981522D0 (no) Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister
DK424385A (da) Aminobenzopyranoner, deres fremstilling og anvendelse som antipsychotiske og anxiolytiske midler
DK568287D0 (da) Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer
DK123786D0 (da) 4-(3-carboxy-3-diazo-2-oxopropyl)-azetidin-2-oner, deres fremstilling og anvendelse som carbapenemantibiotikummellemprodukter
NO874786D0 (no) Optisk aktive gyrasehemmere, deres fremstilling og anvendelse som antibiotika.
DK165552C (da) Carboxylsyreestere, deres fremstilling og anvendelse som insecticider
DK513188D0 (da) Aminosyreestre, deres fremstilling og anvendelse som laegemidler
NO991589D0 (no) Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler
NO893525L (no) Amidoaminsalter av alkenylravsyrederivater, fremgangsmaater for deres fremstilling og deres anvendelse som korrosjonsinhibitorer.
DK437287D0 (da) 2,3-dihydrofuranderivater, deres fremstilling og deres anvendelse som mellemprodukter til fremstilling af tetrahydrofuranderivater
DK198287D0 (da) 3-amino-2-cyanacrylsyreestere, fremgangdsmaade til deres fremstilling og deres anvendelse som hebicider
DK0434020T3 (da) 2,19-Methylenoxy- og 2,19-methylenthiobroforbundne steroider og deres anvendelse som inhibitorer af aromatase og 19-hydroxylase